Issue 6 | 11 November, 2020

Evolving privacy programs to account for disparities across jurisdictions

Joshua Kotok, Chief Risk and Compliance Officer, First Savings provides his insight on developing privacy programs, working across jurisdictions, staying ahead of change, the relationship between data portability and privacy and future outlook for privacy regulation. Click here to view the full interview


US election: Is it time to adjust your loan portfolio strategy?

Join Cushman & Wakefield, Deutsche Bank, Citi and more as we discuss the economic impact of the US election and impacts of political change on banking. Taking place November 17, 10:30 EST/3:30pm GMT – Register for your complimentary pass here.


Latest updates and industry trends within credit risk

Maria Kostova, Credit Risk Specialist, ECB provided a presentation at the 2020 Virtual Risk EMEA Convention, in answer to the influx of questions she received, Maria has completed an article to address each, covering areas including: default definition changes, impact of COVID-19 and regulatory change, negative interest rates, measurement and management of credit risk and much more. Read full article here.


Global stocks climb to record high after Biden presidency optimism

On Monday, global stock and oil prices climbed as markets optimism grew for future of US economic and foreign policy stability under President-elect Joe Biden.



Ant Groups suspension of listing and impact of changes to fintechs
After Ant Group's suspension of its $37Bn listing last week, China Banking and Insurance Regulatory Commission also suggested it would begin treating fintechs more like banks in a move that would drastically impact valuations and attractiveness to investors.



Reducing costs whilst achieving LIBOR remediation
The remediation of contracts involving LIBOR is one of the most significant challenges facing the financial sector. Contract Management Lifecycle is a key part of the process and Hitachi is uniquely placed to address the required functionality and meet this regulatory requirement, whilst accelerating digital transformation.  


Pfizer’s Covid-19 vaccine proves 90% effective in latest trials

In the first milestone for the vaccine developers, Pfizer announced the latest development after testing on 43,500 people in 6 countries. The breakthrough was described as “a great day for science and humanity” as discussion continues on when approval could be granted.

Events & Webinars:
Cushman & Wakefield
Global TPRM: Cross Industry

Update your email preferences here